Radar Telegram alerts Open Radar

The arrival of new products on the market during the war and the holidays, the production wheels of Fars Daro did not stop even for an hour. According to Ahmadi, CEO of Ozav, at the press conference to mark the 66th anniversary of the establishment of this pharmaceutical company, the agenda is to renovate worn out infrastructures and strengthen the supply of liquidity through international markets and exports to neighboring countries and Africa. The Fars Daru R&D unit is in the best position among the Shafa holding companies. This collection has managed to obtain new licenses and 9 products are in the scale phase. It is expected that by the end of this year at least 9 new product licenses will be received, some of which will enter Iran's drug list for the first time. This company earned an income of 401 billion tomans in the river 1405. The total income of Fars Daru in fiscal year 1405 reached 3485 billion tomans, which indicates the continued financial turnover of this pharmaceutical company in the context of the country's economy.

תרגם לעברית

بورس۲۴ · Bourse24 · · Source

🇮🇷 Iran · Map

The arrival of new products on the market during the war and the holidays, the production wheels of Fars Daro did not stop even for an hour. According to Ahmadi, CEO of Ozav, at the press conference to mark the 66th anniversary of the establishment of this pharmaceutical company, the agenda is to renovate worn out infrastructures and strengthen the supply of liquidity through international markets and exports to neighboring countries and Africa. The Fars Daru R&D unit is in the best position among the Shafa holding companies. This collection has managed to obtain new licenses and 9 products are in the scale phase. It is expected that by the end of this year at least 9 new product licenses will be received, some of which will enter Iran's drug list for the first time. This company earned an income of 401 billion tomans in the river 1405. The total income of Fars Daru in fiscal year 1405 reached 3485 billion tomans, which indicates the continued financial turnover of this pharmaceutical company in the context of the country's economy.

The arrival of new products on the market during the war and the holidays, the production wheels of Fars Daro did not stop even for an hour. According to Ahmadi, CEO of Ozav, at the press conference to mark the 66th anniversary of the establishment of this pharmaceutical company, the agenda is to renovate worn out infrastructures and strengthen the supply of liquidity through international markets and exports to neighboring countries and Africa. The Fars Daru R&D unit is in the best position among the Shafa holding companies. This collection has managed to obtain new licenses and 9 products are in the scale phase. It is expected that by the end of this year at least 9 new product licenses will be received, some of which will enter Iran's drug list for the first time. This company earned an income of 401 billion tomans in the river 1405. The total income of Fars Daru in fiscal year 1405 reached 3485 billion tomans, which indicates the continued financial turnover of this pharmaceutical company in the context of the country's economy.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram